Vor Biopharma Inc. financial data

Symbol
VOR on Nasdaq
Location
100 Cambridgepark Drive, Suite 101, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 477 % -33.8%
Debt-to-equity -118 % -394%
Return On Equity 275 %
Return On Assets -1.55K % -2040%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 10.4M shares -84.8%
Common Stock, Shares, Outstanding 9.03M shares -86.9%
Entity Public Float 44.9M USD -67%
Common Stock, Value, Issued 15K USD +114%
Weighted Average Number of Shares Outstanding, Basic 6.68M shares +95.2%
Weighted Average Number of Shares Outstanding, Diluted 6.68M shares +95.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 328M USD +269%
General and Administrative Expense 39.3M USD +34.9%
Operating Income (Loss) -367M USD -211%
Nonoperating Income (Expense) -1.3B USD -23565%
Net Income (Loss) Attributable to Parent -2.45B USD -2078%
Earnings Per Share, Basic -127 USD/shares -1270%
Earnings Per Share, Diluted -127 USD/shares -1270%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 160M USD +204%
Marketable Securities, Current 10M USD -0.11%
Cash, Cash Equivalents, and Short-term Investments 171M USD +171%
Other Assets, Current 1.28M USD +348%
Assets, Current 172M USD +156%
Property, Plant and Equipment, Net 271K USD -96.4%
Operating Lease, Right-of-Use Asset 3.04M USD -91.6%
Other Assets, Noncurrent 269K USD -89.3%
Assets 176M USD +51.9%
Accounts Payable, Current 885K USD -32.8%
Employee-related Liabilities, Current 3.03M USD -26.9%
Accrued Liabilities, Current 17.7M USD +100%
Liabilities, Current 18.8M USD +31.3%
Operating Lease, Liability, Noncurrent 2.81M USD -90.2%
Liabilities 2.4B USD +5481%
Accumulated Other Comprehensive Income (Loss), Net of Tax 12K USD -82.4%
Retained Earnings (Accumulated Deficit) -2.88B USD -575%
Stockholders' Equity Attributable to Parent -2.23B USD -3150%
Liabilities and Equity 176M USD +51.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.1M USD -1.97%
Net Cash Provided by (Used in) Financing Activities -606K USD -731%
Net Cash Provided by (Used in) Investing Activities -230K USD -101%
Common Stock, Shares Authorized 800M shares +100%
Common Stock, Shares, Issued 9.03M shares -86.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -31.9M USD -335%
Deferred Tax Assets, Valuation Allowance 139M USD +33.3%
Deferred Tax Assets, Gross 149M USD +28.6%
Operating Lease, Liability 3.06M USD -90.7%
Depreciation 4.61M USD +28.1%
Payments to Acquire Property, Plant, and Equipment 231K USD +103%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -2.45B USD -2085%
Lessee, Operating Lease, Liability, to be Paid 40.2M USD -14.1%
Property, Plant and Equipment, Gross 272K USD -98.5%
Operating Lease, Liability, Current 252K USD -93.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.68M USD +0.45%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.65M USD +0.93%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure -24.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.38M USD -24.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.88M USD +3.01%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 7.09M USD +2.99%
Operating Lease, Payments 1.69M USD +2.99%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 10.1M USD -13.5%
Share-based Payment Arrangement, Expense 13.5M USD +34.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%